布地奈德联合孟鲁司特对哮喘患者肺功能及免疫功能的影响分析

目的探讨布地奈德联合孟鲁司特对哮喘患者进行干预后患者肺功能及免疫功能的变化.方法将80例哮喘患者分为观察组和对照组,对照组采用布地奈德雾化吸入,观察组在对照组基础上服用孟鲁司特片;在治疗前及治疗结束2周后观察患者肺功能、血清IL-4及INF-γ、外周血Ig E和嗜酸性粒细胞(EOS)水平.结果治疗后两组患者FEV1,FEV1/FVC及PEF均显著升高(P0.05),且观察组升高水平显著高于对照组(P0.05);治疗后患者血清中IL-4水平显著降低(P0.05),INF-γ显著升高(P0.05),且观察组患者IL-4降低水平及INF-γ升高水平均显著高于对照组(P0.05);治疗后两组患者外周血Ig E及EOS水平均显著降低(P0.05),且观察组患者降低水平显著高于对照组(P0.05).结论应用布地奈德联合孟鲁司特对哮喘患者进行治疗,可有效改善患者肺功能及免疫功能,提高临床疗效.

Analysis on the Effects of Budesonide Combined with Montelukast on the Immune Function and Pulmonary Function in Patients with Asthma

Objective To explore the changes of lung function and immune function in patients with asthma intervened by Budesonide combined with Montelukast. Method 80 cases of asthma patients were divided into two groups,the observation group and the control group. The control group was treated with aerosol inhalation of Budesonide,and the observation group was treated with Montelukast tablets on the basis of the control group. Before and after two weeks of treatment,pulmonary function,the levels of serum IL-4,INF-γ,peripheral blood IgE and eosinophilia ( EOS) of the patients were observed. Results After treatment,FEV1 ,FEV1/FVC and the peak expiratory flow (PEF) of the two groups of patients all significantly increased (P<0. 05),and the increased level of the observation group was significantly higher than that of the control group (P<0. 05). After treatment,the level of serum IL-4 decreased significantly (P<0. 05),and INF-γ level increased significantly (P<0. 05),and the changes of the observation group were both obviously higher than those of the control group ( P<0 . 05 ) . After the treatment,the levels of peripheral blood IgE and EOS were significantly lower in the two groups (P<0. 05), and the reduced levels of the observation group were significantly higher than those of the control group ( P<0. 05). Conclusion Budesonide combined with Montelukast on the treatment of asthma can effectively improve the patients’ pulmonary function and immune function,and improve the clinical efficacy.